Advertisement
Screener

CEPHALON INC Patents: Applications Rejected

CEPHALON INC Patent Applications Rejected

26 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2020-09-09: Application 17015175; Invention LIQUID FORMULATIONS OF BENDAMUSTINE; Applicant Cephalon, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2020-03-31: Application 16835562; Invention LIQUID FORMULATIONS OF BENDAMUSTINE; Applicant Cephalon, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2019-11-18: Application 16686751; Invention NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE; Applicant Cephalon, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2019-10-14: Application 16601293; Invention LIQUID FORMULATIONS OF BENDAMUSTINE; Applicant Cephalon, Inc.; Status Abandoned -- Incomplete Application (Pre-examination).
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2020-09-0917015175LIQUID FORMULATIONS OF BENDAMUSTINECephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20210113530A1
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
KANTAMNENI, SHOBHA
2020-03-3116835562LIQUID FORMULATIONS OF BENDAMUSTINECephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20210008035A1
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
KANTAMNENI, SHOBHA
2019-11-1816686751NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDECephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20200323824A1
Martin Ian Cooper
Laurent D. Courvoisier
Mark Eddleston
Robert E. McKean
United Kingdom
United States
United Kingdom
United States
HEYER, DENNIS
2019-10-1416601293LIQUID FORMULATIONS OF BENDAMUSTINECephalon, Inc.Abandoned -- Incomplete Application (Pre-examination)
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
2019-06-2416449612Prodrugs of ChlorokynureninesCEPHALON, INC.Abandoned -- Failure to Respond to an Office ActionUS20190308934A1
Ralph Laufer
Gregory R. Ott
Israel
United States
ANDERSON, REBECCA L
2019-06-0616433510LIQUID FORMULATIONS OF BENDAMUSTINECephalon, Inc.Abandoned -- Incomplete Application (Pre-examination)
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
2019-01-1116245672LIQUID FORMULATIONS OF BENDAMUSTINECephalon, Inc.Abandoned -- Incomplete Application (Pre-examination)
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
2018-06-1916012417BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSCEPHALON, INC.Abandoned -- Failure to Respond to an Office ActionUS20180296534A1
Jason Edward Brittain
Joe Craig Franklin
United States
United States
PEEBLES, KATHERINE
2018-03-0115756692PRODRUGS OF CHLOROKYNURENINESCEPHALON, INC.Abandoned -- Failure to Respond to an Office ActionUS20180327351A1
Ralph LAUFER
Gregory R. OTT
Israel
United States
ANDERSON, REBECCA L
2017-08-2915689299Inhalation Systems, Devices and MethodsCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180056018A1
Janice M.G. Canvin
Marla D. Curran
Robert B. Noble
Saku JP Torvinen
James Zangrilli
United Kingdom
United States
United States
Finland
United States
LE, NATHAN MINH
2016-10-1315292468MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORSCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170027948A1
Henry J. Breslin
Bruce D. Dorsey
Gregory R. Ott
United States
United States
United States
JEAN-LOUIS, SAMIRA JM
2016-08-0915232084PYRROLOTRIAZINES AS ALK INHIBITORSCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160347756A1
Ralph C. Haltiwanger
Eugen F. Mesaros
Gregory R. Ott
United States
United States
United States
DAVIS, BRIAN J
2016-06-0915102896TREATMENT OF MULTIPLE SCLEROSIS WITH A 1,2,4-TRIAZOLO [1,5A] PYRIDINE DERIVATIVECEPHALON, INC.Abandoned -- Failure to Respond to an Office ActionUS20160303116A1
Pawel T. DOBRZANSKI
Joel KAYE
Arie ORBACH
Bruce A. RUGGERI
Matthew M. SEAVEY
United States
Israel
Israel
United States
United States
CHANDRAKUMAR, NIZAL S
2015-09-1014849719Child Resistant Cover for Oral Dosage FormsCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160001957A1
Randy J. Bradway
Gerald A. Frank
United States
United States
DARB, HAMZA A.
2015-09-0414845564BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSCEPHALON, INC.Abandoned -- Failure to Respond to an Office ActionUS20150374671A1
Jason Edward Brittain
Joe Craig Franklin
United States
United States
PEEBLES, KATHERINE
2015-08-2114831998Tricyclic Derivatives and Their Pharmaceutical Use and CompositionsCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150368257A1
Shawn P. Allwein
George C. Morton
Gerard C. Rosse
Yi Wang
United States
United States
United States
United States
RICCI, CRAIG D
2015-07-3114814570Liquid Formulations of BendamustineCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150335750A1
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
KANTAMNENI, SHOBHA
2014-11-0314531023Novel Solid Forms Of Bendamustine HydrochlorideCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20150051258A1
Martin Ian Cooper
Laurent D. Courvoisier
Mark Eddleston
Robert E. McKean
United Kingdom
United States
United Kingdom
United States
HEYER, DENNIS
2014-03-2114221422Liquid Formulations Of BendamustineCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140206733A1
Anthony S. Drager
Rachel Y. Labell
Piyush R. Patel
United States
United States
United States
KANTAMNENI, SHOBHA
2014-03-1214207465Solid State Forms of 6-[4-[3-((R)-2-Methylpyrrolidine-1-yl)-propoxy]phenyl] 2H-pyridazine-3-one HydrochlorideCephalon Inc.Abandoned -- Failure to Respond to an Office ActionUS20140275102A1
Stephen J. Bierlmaier
Laurent Courvoisier
Ralph C. Haltiwanger
Martin J. Jacobs
United States
United States
United States
YOO, SUN JAE
2014-01-3114169961BENDAMUSTINE PHARMACEUTICAL COMPOSITIONSCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140148490A1
Jason Edward Brittain
Joe Craig Franklin
United States
United States
PEEBLES, KATHERINE
2014-01-0914151242Liquid Formulations Of BendamustineCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140128443A1
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
KANTAMNENI, SHOBHA
2013-11-2014084768Liquid Formulations of BendamustineCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140080881A1
Anthony S. Drager
Rachel Y. LaBell
Piyush R. Patel
United States
United States
United States
KANTAMNENI, SHOBHA
2013-07-2413949323SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDSCephalon, Inc.Abandoned -- Failure to Respond to an Office ActionUS20130310389A1
Reddeppa reddy Dandu
Robert L. Hudkins
Babu G. Sundar
United States
United States
United States
RAMACHANDRAN, UMAMAHESWARI
2013-02-2113773016Modafinil FormulationsCEPHALON, INC.Abandoned -- Failure to Respond to an Office ActionUS20130156825A1
Moshe Bentolila
Aldo Shusterman
Moshe Arkin
Joseph Kaspi
Israel
Israel
Israel
Israel
LIU, SUE XU
2013-01-0913737213Methods for the Sterilization of BendamustineCEPHALON, INC..Abandoned -- Failure to Respond to an Office ActionUS20130144068A1
Rachel Y. LaBell
Piyush R. Patel
United States
United States
SPAMER, DONALD R